In IO patients with severe myocardial infarction and left ventricular failure, bretylium tosylate was used in the treatment of ventricular arrhythmias which had proved refractory to lignocaine and procainamide; 6 cases had also failed to respond to phenytoin. In 7 patients stable sinus rhythm was achieved and 5 of these survived to leave hospital. For the period during which bretylium was used, the only observed side-effect was sinus bradycardia.
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The anti-arrhythmic effect of bretylium tosylate was first described in I965 when Leveque reported its protective effect in experimentally-induced atrial fibrillation in dogs. In the following year, Bacaner (1966) showed that bretylium protected the dog heart against ventricular fibrillation by raising the fibrillation threshold, and later demonstrated (Bacaner, I968a) that it was more effective in this respect than lignocaine, procainamide, quinidine, phenytoin, and propranolol. Since then, the use of bretylium for the treatment and prophylaxis of cardiac arrhythmias in man following myocardial infarction and cardiac surgery has been reported in the United States (Bacaner, i968b; Richards and Jerde, I969; Castaneda and Bacaner, I969) .
Over the past I2 months we have encountered I0 patients with ventricular arrhythmias complicating severe myocardial infarction in whom conventional anti-arrhythmic therapy was either ineffective or only of temporary benefit. In this report we describe our experience of bretylium in the treatment of these patients.
Patients and Methods
The patients were treated in the Coronary Care Unit of the Royal Infirmary of Edinburgh. Clinical details are summarized in Table i . Myocardial infarction was confirmed in every case by serum enzyme changes and in 9 by the electrocardiogram. The ventricular arrhythmias and treatment before bretylium therapy are shown in Table 2 and in the Figure. Also present in Cases 4, 6, and IO, were multiple 'R on T' ventricular extrasystoles beginning at the apex of the preceding T wave.
All patients were given lignocaine and procainamide, 6 had phenytoin, and i also received propranolol. Lignocaine is used routinely in the treatment and prophylaxis of ventricular arrhythmias in doses of I00-200 mg. intravenously followed by the infusion of I-2 g. over 24 hours. In patients who fail to respond to lignocaine, procainamide is given intravenously up to i g.; if this is unsuccessful phenytoinis injected intravenously, the maximal dose being 250 mg. Following successful conversion to sinus rhythm prophylactic therapy consists of procainamide, 2-3 g. daily given by mouth for 6 weeks.
Bretylium was administered after this regimen of suppressive therapy had failed to prevent recurrent episodes of ventricular arrhythmias, the loading dose being 5 mg. per kg. body weight intramuscularly; in three cases the initial dose was given by slow intravenous injection. The maintenance dose of bretylium was 3 mg. per kg. body weight intramuscularly every 8 to I2 hours. The electrocardiogram was monitored continuously, the blood pressure was recorded hourly, and chest x-ray was taken daily.
Results
The results of bretylium administration in the prophylaxis of refractory recurrent ventricular arrhythmias are summarized in Case Io differed from the others in that numerous 'R on T' extrasystoles occurred within I2 hours of the onset of symptoms. Lignocaine produced nystagmus and dysarthria without decreasing the frequency ofectopic beats. Procainamide given orally was also ineffective and was discontinued after the sixth dose; the first 3 episodes of ventricular fibrillation occurred within iI to 2 hours after the second, fourth, and sixth doses of this drug. Recurrent ventricular fibrillation was unaffected by phenytoin, and bretylium was substituted. Stable sinus rhythm was achieved 40 minutes after the loading dose of bretylium and was maintained for 4 days. Prophylaxis was started with procainamide, but 30 minutes after the first oral dose of 500 mg. there was gross lengthening of the QT interval and T wave distortion, 'R on T' ventricular extrasystoles recurred and ventricular fibrillation developed 30 minutes later. Bretylium was continued for a further 5 days without recurrence of the arrhythmia and further successful prophylaxis was achieved with quinidine.
Deaths Case 4 reverted to sinus rhythm 20 minutes after the first dose of bretylium. The second injection was inadvertently omitted and I8 hours later he had ventricular tachycardia which progressed to fibrillation. After successful defibrillation a maintenance dose of bretylium was given every i2 hours. Eleven hours after the second injection there was repeated ventricular fibrillation with a fatal outcome 24 hours later. Case 6 returned to sinus rhythm 20 minutes after the first injection of bretylium. Thirty-six hours later frequent 'R on T' extrasystoles reappeared and the dose of bretylium was increased to 200mg., 8 hourly. Thereafter sinus rhythm was maintained for a further 6o hours when ventricular fibrillation recurred, terminating in death.
Cases 5 and 9 died of recurrent ventricular fibrillation within 20 minutes of the initial dose of bretylium. Case 2 was given bretylium intravenously to terminate prolonged ventricular tachycardia refractory to lignocaine and procainamide but this had no effect in go minutes. DC shock restored sinus rhythm which was followed in 2 hours by asystole.
Discussion
The results observed in I0 patients suggest that bretylium tosylate can be effective in restoring and maintaining sinus rhythm in some patients with acute myocardial infarction who develop ventricular arrhythmias refractory to conventional treatment. It is not suggested that bretylium should be the first drug for these cases, since lignocaine, procainamide, and phenytoin are satisfactory and effective in the majority. The 5 survivors all maintained a striking stability of sinus rhythm after the use of bretylium; it is unlikely that this effect was coincidental in view of the duration of the arrhythmias before the drug was introduced. Of those who died, Cases 4 and 6 had paroxysmal ventricular tachycardia for 24 hours which ceased 20 minutes after the first injection of bretylium; the maintenance of sinus rhythm for I8 and 36 hours, respectively, suggests that the drug was temporarily beneficial. The variable delay in onset of the anti-arrhythmic effect of bretylium (Bacaner, I966, I968b) may have accounted for the lack of response in Cases 5 and 9, both of whom died within 20 minutes of administration of the loading dose. In Case 2, bretylium given intravenously was unsuccessful in terminating a prolonged episode of ventricular tachycardia.
In 9 of our patients the ventricular arrhythmias were of late onset, occurring 5 to I9 days after myocardial infarction; it is recognized that arrhythmias of this type associated with left ventricular failure are often difficult to suppress and carry a poor prognosis (Lawrie, I968) . Though such arrhythmias may result from further infarction (Spracklen et al., I968) , there was no clinical, biochemical, or electrocardiographic evidence of recurrence in any of our patients. All patients were treated for cardiac failure, and received digoxin and diuretic therapy with supplements of potassium chloride; in each case plasma potassium levels remained normal throughout treatment. Though digitalis toxicity cannot be excluded as a causative factor in these ventricular arrhythmias, the amount of digoxin administered was not considered excessive and there were no other features of toxicity. In Case io it is probable that procainamide predisposed to ventricular fibrillation by prolonging the QT interval (Cohen, I966) .
Bretylium tosylate is an adrenergic neuronal blocking agent. It was introduced in group.bmj.com on June 23, 2017 -Published by http://heart.bmj.com/ Downloaded from factory because of unreliable absorption from the gastro-intestinal tract and tolerance to its hypotensive effect. Significant lowering of blood pressure was not observed after bretylium administration in any of our patients (Table 3 ) but sinus bradycardia occurred in Cases 3 and IO. The patients were treated in bed and the effect of posture on the blood pressure was not determined. The antifibrillatory properties of bretylium may be related to hyperpolarization and improved conduction velocity (Watanabe, Josipovic, and Dreifus, I968) . Bretylium differs from quinidine-like compounds both in its electrophysiological effect and in its lack of local anaesthetic properties (Papp and Vaughan Williams, I969) .
